LLY

986.45

+0.17%↑

JNJ

242.9

+0.54%↑

ABBV

221.34

+0.76%↑

NVS

154.3

+0.79%↑

AZN

191.97

+0.98%↑

LLY

986.45

+0.17%↑

JNJ

242.9

+0.54%↑

ABBV

221.34

+0.76%↑

NVS

154.3

+0.79%↑

AZN

191.97

+0.98%↑

LLY

986.45

+0.17%↑

JNJ

242.9

+0.54%↑

ABBV

221.34

+0.76%↑

NVS

154.3

+0.79%↑

AZN

191.97

+0.98%↑

LLY

986.45

+0.17%↑

JNJ

242.9

+0.54%↑

ABBV

221.34

+0.76%↑

NVS

154.3

+0.79%↑

AZN

191.97

+0.98%↑

LLY

986.45

+0.17%↑

JNJ

242.9

+0.54%↑

ABBV

221.34

+0.76%↑

NVS

154.3

+0.79%↑

AZN

191.97

+0.98%↑

Начало・Списък с акции・Voyager Therapeutics Inc

Voyager Therapeutics Inc

Затворен

4.28 -3.39

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

4.25

Максимум

4.47

Ключови измерители
By Trading Economics
Приходи	5.5M -28M
Продажби	8.2M 13M
Марж на печалбата	-208.694
Служители	172
EBITDA	8.7M -27M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+228.92% upside

Дивиденти
By Dow Jones
Следващи печалби	4.05.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-26M 229M
Предишно отваряне	7.67
Предишно затваряне	4.28

Техническа оценка

By Trading Central

Увереност

Bearish Evidence

3.17 / 3.4644 Подкрепа & съпротива

Voyager Therapeutics Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

16.03.2026 г., 21:37 ч. UTC

Придобивния, сливания и поглъщания

Lensar and Alcon Agree to Terminate Merger

16.03.2026 г., 19:06 ч. UTC

Значими събития в новините

Mideast Loses 12 Million Boe/d Following Hormuz Closure: Rystad -- OPIS

16.03.2026 г., 17:44 ч. UTC

Придобивния, сливания и поглъщания

Novartis Issues Debt Offering to Help Fund $12 Billion Acquisition of Avidity Biosciences

16.03.2026 г., 23:46 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

16.03.2026 г., 23:46 ч. UTC

Пазарно говорене

Nikkei May Rise After Oil Prices Decline -- Market Talk

16.03.2026 г., 23:37 ч. UTC

Пазарно говорене

Gold Edges Higher on Possible Technical Recovery -- Market Talk

16.03.2026 г., 23:05 ч. UTC

Пазарно говорене

Slumping Consumer Confidence Highlights Risk Around RBA Hike -- Market Talk

16.03.2026 г., 21:56 ч. UTC

Пазарно говорене

DUG Technology's Stock Fall Creates Opportunity -- Market Talk

16.03.2026 г., 21:41 ч. UTC

Пазарно говорене

Значими събития в новините

Global Equities Roundup: Market Talk

16.03.2026 г., 21:41 ч. UTC

Пазарно говорене

Значими събития в новините

Clouds Gather Over Auckland Intl Airport as Airlines Up Fares -- Market Talk

16.03.2026 г., 20:59 ч. UTC

Придобивния, сливания и поглъщания

Alcon: Transaction Unattractive to Pursue Further in Light of FTC's Opposition

16.03.2026 г., 20:59 ч. UTC

Придобивния, сливания и поглъщания

Alcon: Delay and Associated Costs of Extended Regulatory Review Has Rendered Deal Unattractive to Pursue Further

16.03.2026 г., 20:59 ч. UTC

Придобивния, сливания и поглъщания

Alcon Entered Agreement With LENSAR to Terminate Merger Agreement

16.03.2026 г., 20:57 ч. UTC

Придобивния, сливания и поглъщания

Alcon and LENSAR, Inc. Agree to Terminate Merger Agreement

16.03.2026 г., 20:51 ч. UTC

Придобивния, сливания и поглъщания

Nvidia-Backed Nscale Plans Huge Data Center Cluster in West Virginia -- WSJ

16.03.2026 г., 20:50 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk

16.03.2026 г., 20:50 ч. UTC

Пазарно говорене

Значими събития в новините

Energy & Utilities Roundup: Market Talk

16.03.2026 г., 20:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

16.03.2026 г., 20:50 ч. UTC

Пазарно говорене

Health Care Roundup: Market Talk

16.03.2026 г., 19:53 ч. UTC

Значими събития в новините

U.S. Allies Rebuff Trump's Demand for Help Opening Strait of Hormuz -- WSJ

16.03.2026 г., 19:43 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

16.03.2026 г., 19:43 ч. UTC

Пазарно говорене

Nvidia Sees $1 Trillion in Blackwell, Rubin Orders Through 2027 -- Market Talk

16.03.2026 г., 19:37 ч. UTC

Пазарно говорене

Значими събития в новините

Natural Gas Follows Oil Prices Lower -- Market Talk

16.03.2026 г., 19:20 ч. UTC

Значими събития в новините

Stock Market Today: Dow Jumps, Brent Crude Pulls Back From $105 -- WSJ

16.03.2026 г., 19:17 ч. UTC

Пазарно говорене

Значими събития в новините

Crude Oil Sinks on Signals from Strait of Hormuz -- Market Talk

16.03.2026 г., 19:00 ч. UTC

Пазарно говорене

Bank of Canada Needs Dovish Approach Based on Weak Data -- Market Talk

16.03.2026 г., 18:23 ч. UTC

Пазарно говорене

LME Restarts Trading After Outage -- Market Talk

16.03.2026 г., 17:36 ч. UTC

Значими събития в новините

Oil Prices Fall as Trump Says Hormuz Help Is Coming. Tankers Getting Through, Bessent Adds. -- Barrons.com

16.03.2026 г., 17:19 ч. UTC

Пазарно говорене

Grains Sink as Investors Steer Toward Equities -- Market Talk

16.03.2026 г., 17:14 ч. UTC

Значими събития в новините

Trump Ends News Conference

Сравнение с други в отрасъла

Ценова промяна

Voyager Therapeutics Inc Прогноза

Ценова цел

By TipRanks

228.92% нагоре

12-месечна прогноза

Среден 14.67 USD 228.92%

Висок 25 USD

Нисък 8 USD

Според 7 анализатори от Wall Street, предложили 12-месечна ценова цел за Voyager Therapeutics Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

7 ratings

Купи

Задържане

Продай

Според 7 анализатори, дали борсови рейтинги на Voyager Therapeutics Inc през последните 3 месеца.

Техническа оценка

By Trading Central

3.17 / 3.4644Подкрепа & съпротива

Recent bearish events outweigh bullish events.

All events are bearish.

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Voyager Therapeutics Inc

Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.